On November 1, 2022 VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products reported the publication of data from the Clinical Trial P-VCNA-002 conducted in patients with Pancreatic Cancer that received VCN-01 by intratumorally administration (Press release, VCN Biosciences, NOV 1, 2022, View Source [SID1234606778]). The paper appears in Peer-Reviewed Journal of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights from the article include:

➢ Treatment based in three intratumoral doses of VCN-01 is generally well-tolerated.

➢ VCN-01 treatment results in disease stabilization of injected lesions.

➢ VCN-01 is detected in blood as secondary peaks and in post-treatment tumor biopsies, indicating active virus replication.

➢ Patients present increasing levels of hyaluronidase in sera over time which confirm sustained intratumor VCN-01 replication

➢ VCN-01 decreases tumor stiffness in pancreatic patients, suggesting stromal disruption

Manel Cascalló, CEO of VCN Biosciences, said, "We are very excited to publish our clinical data obtained with VCN-01 by intratumor route in patients with pancreatic cancer. The product has demonstrated a good safety profile when combined with the standard chemotherapy for this tumor type, and we have been preliminary evidence of its capacity to control the growth of this extremely aggressive tumor. Although this trial was designed as a Proof of Concept study, it has allowed to confirm the mechanism of action of VCN-01 in the clinicals setting. We also want to thank patients and families for their willingness to participate in the clinical trial."

The publication is now available electronically at: VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects | Journal for ImmunoTherapy of Cancer (bmj.com)

On November 1, 2021 Patrys has reported a $7.8 million capital raising via a Placement and fully underwritten Rights Issue (Press release, Patrys, NOV 1, 2021, View Source [SID1234605548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These funds will significantly strengthen Patrys’ balance sheet, providing for:

Initiation of a formal development program for PAT-DX3, Patrys’ full-sized IgG deoxymab antibody, that is expected to provide Patrys with additional development and partnering opportunities;
Development of a manufacturing process to provide clinical‑grade PAT-DX3 at commercial scale including establishing a stable, high-yielding producer cell line.
Further R&D studies including use of deoxymabs for targeted delivery to support potential inhouse and partnered programs for antibody drug conjugates (ADCs);
Expansion of the Company’s business development activities, working capital, corporate activities, and offer costs.
Territory Funds Management has strongly supported this capital raise and we are pleased to offer existing shareholders an opportunity to invest in this exciting growth opportunity too via the fully underwritten 1:12 Rights Issue.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 1, 2021 KQ Labs reported that a programme delivered by the Francis Crick Institute and funded by LifeArc, is proud to announce its first exit as Glamorous AI, a company that was part of KQ Labs’ third cohort, has been acquired by X-Chem, the US based global leader in DNA-encoded library (DEL) driven discovery solutions(Press release, LifeArc, NOV 1, 2021, View Source [SID1234594651]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Glamorous AI is a leader in artificial intelligence (AI) solutions for drug discovery. GlamorousAI is radically changing how drugs are designed and optimised using their proprietary artificial intelligence platform, RosalindAI, and applying it to low and sparse data problems inherent to drug discovery.

X-Chem is the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery and the first to demonstrate applying machine learning to large, high quality, DEL datasets can accelerate hit generation. The acquisition of the innovative AI capabilities of Glamorous AI positions X-Chem as a leading service provider in machine learning-driven drug discovery.

Noor Shaker, CEO and Founder of Glamorous AI said: "Glamorous AI is one of a few fortunate startups to have been accepted to the KQ labs programme. The programme provided a great opportunity to be part of an innovative ecosystem and connect with likeminded founders looking to transform the life sciences industry. With its focus on healthcare and life sciences, the programme has helped us build and strengthen our connections with the industry."

Barbara Domayne-Hayman, who leads the KQ Labs programme, commented: "We are very excited that Glamorous AI has achieved this excellent result, and in such a short space of time. The greater resources that X-Chem can bring will enable wider uptake of Glamorous AI’s platform technology. We wish the Glamorous AI team every success in their next phase as they transition to the X-Chem organisation".